The acquisition bid follows in the footsteps of Calliditas recently winning FDA approval for Tarpeyo, its primary immunoglobulin A nephropathy (IgAN) treatment.
Biogen will make an upfront payment of $1.15 billion to HI-Bio and the latter’s stockholders will be eligible for payments of up to an additional $650 million.
AI Deciphered: Discovering the Potential for Marketers and Communicators